DNA based vaccination with a cocktail of plasmids encoding immunodominant Leishmania (Leishmania) major antigens confers full protection in BALB/c mice

被引:25
作者
Ahmed, Sami Ben Hadj [1 ]
Touihri, Leila [1 ]
Chtourou, Yessine [1 ]
Dellagi, Koussay [1 ]
Bahloul, Chokri [1 ]
机构
[1] Inst Pasteur, Lab Immunol Vaccinol & Mol Genet, Tunis 1002, Tunisia
关键词
Leishmania major; DNA vaccine; Cocktail; Protection; MURINE CUTANEOUS LEISHMANIASIS; IMMUNE-RESPONSE; VISCERAL LEISHMANIASIS; INFECTION; INFANTUM; CHALLENGE; VACCINES; DONOVANI; PROTEIN; REQUIREMENTS;
D O I
10.1016/j.vaccine.2008.10.013
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Despite the lack of effective vaccines against parasitic diseases, the prospects of developing a vaccine against leishmaniasis are still high. With this objective, we have tested four DNA based candidate vaccines encoding to immunodominant leishmania antigens (LACKp24, TSA, LmSTI1 and CPa). These candidates have been previously reported as capable of eliciting at least partial protections in the BALB/c mice model of experimental cutaneous leishmaniasis. When tested under similar experimental conditions, all of them were able to induce similar partial protective effects, but none could induce a full protection. In order to improve the level of protection we have explored the approach of DNA based vaccination with different cocktails of plasmids encoding to the different immunodominant Leishmania antigens. A Substantial increase of protection was achieved when the cocktail is composed of all of the four antigens; however. no full protection was achieved when mice were challenged with a high dose of parasite in their hind footpad. The full protection was only achieved after a challenge with a low parasitic dose in the dermis of the ear. It was difficult to determine clear protection correlates, other thin the mixture Of immunogens induced specific Th1 immune responses against each component. Therefore, such an association of antigens increased the number of targeted epitopes by the immune system with the prospects that the responses are at least additive if not synergistic. Even though, any extrapolation of this approach when applied to other animal or human models is rather hazardous, it undoubtedly increases the hopes of developing an effective leishmania vaccine. (c) 2008 Elsevier Ltd. All rights reserved.
引用
收藏
页码:99 / 106
页数:8
相关论文
共 41 条
[31]  
Rogers KA, 2002, FEMS MICROBIOL LETT, V209, P1, DOI 10.1111/j.1574-6968.2002.tb11101.x
[32]   Evasion of innate immunity by parasitic protozoa [J].
Sacks, D ;
Sher, A .
NATURE IMMUNOLOGY, 2002, 3 (11) :1041-1047
[33]   Immunogenicity of a multicomponent DNA vaccine against visceral leishmaniasis in dogs [J].
Saldarriaga, OA ;
Travi, BL ;
Park, W ;
Perez, LE ;
Melby, PC .
VACCINE, 2006, 24 (11) :1928-1940
[34]   Evaluation of the murine immune response to Leishmania meta 1 antigen delivered as recombinant protein or DNA vaccine [J].
Serezani, CHC ;
Franco, AR ;
Wajc, M ;
Yokoyama-Yasunaka, JKU ;
Wunderlich, G ;
Borges, MM ;
Uliana, SRB .
VACCINE, 2002, 20 (31-32) :3755-3763
[35]   Vaccination with recombinant Parasite Surface Antigen 2 from Leishmania major induces a Th1 type of immune response but does not protect against infection [J].
Sjölander, A ;
Baldwin, TM ;
Curtis, JM ;
Bengtsson, KL ;
Handman, E .
VACCINE, 1998, 16 (20) :2077-2084
[36]   Protective efficacy of a tandemly linked, multi-subunit recombinant leishmanial vaccine (Leish-111f) formulated in MPL® adjuvant [J].
Skeiky, YAW ;
Coler, RN ;
Brannon, M ;
Stromberg, E ;
Greeson, K ;
Crane, RT ;
Campos-Neto, A ;
Reed, SG .
VACCINE, 2002, 20 (27-28) :3292-3303
[37]  
SOBIE L, 2000, P NATL ACAD SCI USA, V97, P8427
[38]   Vaccination with DNA encoding ORFF antigen confers protective immunity in mice infected with Leishmania donovani [J].
Sukumaran, B ;
Tewary, P ;
Saxena, S ;
Madhubala, R .
VACCINE, 2003, 21 (11-12) :1292-1299
[39]   Genetic immunization with glycoprotein 63 cDNA results in a helper T cell type 1 immune response and protection in a murine model of leishmaniasis [J].
Walker, PS ;
Scharton-Kersten, T ;
Rowton, ED ;
Hengge, U ;
Bouloc, A ;
Udey, MC ;
Vogel, JC .
HUMAN GENE THERAPY, 1998, 9 (13) :1899-1907
[40]   GENETIC VACCINATION AGAINST LEISHMANIASIS [J].
XU, D ;
LIEW, FY .
VACCINE, 1994, 12 (16) :1534-1536